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ABSTRACT
The role played by the interaction of nitric oxide (NO) and 
endothelins (ET) in the modulation of airway function, and
the modulation ofβ-ad renergic-mediated bronchodilator
responses by ascorbic acid in the presence or absence of 
endogenous NO induced by ET in anesthetized guinea-pigs was 
examined. Endothelins induced a concentration-dependent 
increase in respiratory resistance, and pretreatment with the NO 
synthase inhibitor, NG-nitro-L-arginine methylester, (L-NAME),
significantly increased ET-mediated bronchoconstriction. In 
addition, ET-3-mediated bronchoconstriction following pretreat-
ment with L-NAME was reversed by L-arginine. These findings 
suggest that the response to the administration of ET-3 can be 
attributed to the release of NO from the guinea-pig airway. 
Neither inhaled isoproterenol nor salbutamol significantly 
affected ET-3-mediated bronchoconstriction, but pretreatment 
with L-NAME markedly enhanced isoproterenol-mediated bron-
chodilatation. These findings suggest that endogenous NO 
induced by ET-3 may attenuate isoproterenol-mediated bron-
chodilator responses. Ascorbic acid, an antioxidant, enhanced 
isoproterenol-mediated bronchodilator responses following pre-
contraction with ET-3, but pretreatment with L-NAME reduced 
this effect of ascorbic acid. The findings suggest that ascorbic
acid attenuates the effect of endogenous NO onβ-ad re ergic-
mediated bronchodilator response via its antioxidant activity. 
Since 10-7mol/L ET-1 does not induce the release of NO from 
the guinea-pig airway, ascorbic acid cannot enhance isopro-
terenol-mediated bronchodilator responses. It seems likely 
that endogenous NO plays an important regulatory role in
modulating β-adrenergic-mediated bronchodilator responses in
the airway.
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INTRODUCTION
The endothelins (ET) are a group of physiologically active pep-
tides. Recent studies have demonstrated the existence of three 
separate ET genes in the human genome encoding for three 
specific peptides, namely ET-1, ET-2 and ET-3.1 Recent obser-
vations suggest that these peptides are released from human 
airway epithelial cell cultures in response to endogenous and 
exogenous signals.2 In addition, endothelin receptors are pres-
ent on the airway smooth muscle of animals and humans, and 
their stimulation by endothelins may result in bronchoconstric-
tion.3 Nitric oxide (NO) is formed from the semi-essential amino 
acid L-arginine by the action of the enzyme NO synthase.4 NO 
has been shown to elicit a number of biological responses in the 
lung including arterial vasodilatation and bronchodilatation.5,6 
NO and related compounds increase the level of intracellular 
cyclic guanosine monophosphate (cGMP) and induce relax-
ation of airway smooth muscle in both humans and guinea-
pigs.7 In blood vessels, ET induces strong and long-lasting 
constriction in vivo and in vitro. It has been shown that the three 
forms of ET activate ETB receptors at similar concentrations, 
whereas ET-1 and ET-2 activate ETA receptors at concentrations 
lower than does ET-3.8 ET relaxes vascular smooth muscle, 
which induces the release of NO by activating ETB receptors.9 
These findings suggest that NO may act as a physiological 
antagonist of ET in blood vessel walls. We have attempted to 
determine the role played by the interaction of ET and NO in 
modulation of airway function, and whether ascorbic acid modu-
lates β-adrenergic-mediated bronchodilator responses in the
presence or absence of endogenous NO induced by ET in anes-
thetized guinea-pigs.
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METHODS
Measurement of pulmonary resistance
Male Hartley guinea-pigs weighing 400-500g were used. 
Under sodium pentobarbital anesthesia (50 mg/kg, i. p.; 
Abbott Laboratories, IL, USA), artificial ventilation was per-
formed through a tracheal cannula connected to a constant-
volume ventilator (Model 680, Harvard Apparatus Co., MA, 
USA) at a rate of 60 breaths/min. The tidal volume was set at 6 
mL/kg. Airflow was monitored continuously with a pneumota-
chograph (TV-241T, Nihon Koden Co., Tokyo, Japan) con-
nected to a differential pressure transducer (TP-602T, Nihon 
Koden Co.). The tidal volume was calculated by electrical inte-
gration of airflow. A fluid-filled polyethylene catheter was intro-
duced into the esophagus to measure esophageal pressure as 
an approximation of pleural pressure. Intratracheal pressure 
was measured using a polyethylene catheter inserted into a 
short tube connecting the tracheal cannula to the pneumota-
chograph. Transpulmonary pressure (defined as the difference
between the intratracheal and the esophageal pressure) was 
measured with a differential pressure transducer. Total pul-
monary resistance (RL) was calculated using methods previously 
described.10 Before experiments were performed, guinea-pigs 
were allowed 20 min to recover from the preparation proce-
dure. To prevent alveolar atelectasis, a large inflation of three 
tidal volumes was performed every 5 min by occluding the 
expiratory valve.
Bronchial provocation
Airway resistance was determined by exposing guinea-pigs 
to increasing concentrations of bronchoconstricting agents 
administered directly into the airway via the endotracheal tube. 
Drug aerosols (mass median aerodynamic diameter, 1.8 ƒÊm; 
geometric standard deviation, 2 ƒÊm; output, 1.5 mL/min) were 
generated by an ultrasonic nebulizer (TUR-3200, Nihon 
Koden, Japan) placed on the inspiratory line of the ventilator. 
Concentration-response curves were obtained using the 
following method: after a control challenge with the solvent 
used to prepare the bronchoconstrictor agents, an aerosol of 
this agent was administered throughout several series of 
30 breaths, each series was separated by 5 min intervals. 
Respiratory resistance was measured 30s after the end of each 
nebulization, when the bronchoconstrictor response reached 
its maximum.
The effect of L-NAME on ET-1-, ET-2- or ET-3-
induced bronchoconstriction
In one series of experiments, concentration curves for the 
response to endothelins between 10210 and 1026 mol/L (30 
breaths at each concentration) were recorded for two groups of 
six guinea-pigs each. One group was administered aerosolized
NG-nitro-L-arginine methyl ester (L-NAME) and the other 
aerosolized saline. In another series of experiments, pulmonary 
resistance in response to 1027 mol/L ET-3 was recorded. 
Groups of six guinea-pigs each were given either ET-3 and 
L-NAME (1024 mol/L, 30 breaths), or ET-3, L-NAME and 
L-Arginine (1023 mol/L, 30 breaths).
Effect of L-NAME and ascorbic acid on 
isoproterenol- or salbutamol-induced 
bronchodilation
In each group, guinea-pigs were randomly allocated to pretreat-
ment with either aerosolized L-NAME (administered 20 min 
before ET-inhalation) or saline administered under the same 
condition . We recorded the pulmonary resistance in response 
to isoproterenol (1024 mol/L, 30 breaths) 20 min after ET-3-
administration. In additional experiments we also recorded the 
pul nary resistance in response to the simultaneous aerosolized 
administration of 1024 mol/L isoproterenol or salbutamol and 
1023 mol/L ascorbic acid.
Drugs
L-Arginine was purchased from Wako Pure Chemical Industries 
Ltd (Osaka, Japan). L-NAME, salbutamol and isoproterenol 
were obtained from Sigma Chemical Company (St Louis, MO, 
USA). ET-1, ET-2 and ET-3 were purchased from the Peptide 
Institution, Inc. (Osaka, Japan).
Statistical analysis
All values are expressed as mean± s. e. m. Statistical analysis
was performed by one-way analysis of variance followed by 
Fisher's exact test. Statistical significance was indicated by
P<0.05.
RESULTS
Effect of L-NAME on ET-1-, ET-2- or ET-3-induced 
bronchoconstriction
Baseline respiratory resistance did not differ significantly in guinea-
pigs administered L-NAME, ascorbic acid, or saline. In the 
absence of pretreatment with L-NAME, aerosolized ET induced 
concentration-dependent bronchoconstriction in guinea-pigs in
vivo, and the order of contractile ability was ET-1>ET-2>ET-3 
(Fig. 1). After pretreatment with L-NAME (1024 mol/L), aerosolized 
ET significantly increased bronchocontrac-tile responses com-
pared with those in guinea-pigs administered saline. However, 
high doses of ET-1 and ET-2 (1027 mol/L and 1026 mol/L, respec-
tively) did not have this effect. ET-3 (1027 mol/L)-induced bron-
ch constriction was enhanced by pretreatment with L-NAME and 
was reversed by L-arginine (1023 mol/L; Fig. 2).
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Effect of L-NAME and ascorbic acid on 
isoproterenol- or salbutamol-induced 
bronchodilator response
Aerosolized ET-1 and ET-3 each rapidly induced maximal constric-
tion and subsequently maintained constant airway tone. Neither 
administration of aerosolized ascorbic acid nor isoproterenol sig-
nificantly inhibited ET-3-induced bronchoconstriction, but in the 
presence of ascorbic acid, isoproterenol markedly inhibited ET-3-
induced bronchoconstriction (Fig. 3). However, after treatment 
with L-NAME, aerosolized isoproterenol significantly inhibited ET-
3-induced bronchoconstriction, and no additive bronchodilatative 
effect was obtained by simultaneous aerosolized administration of
ascorbic acid (Fig. 4). Salbutamol, anotherβ-adrenergic agent,
also did not significantly inhibit ET-3-induced bronchoconstriction, 
and the simultaneous aerosolized administration of salbutamol 
and ascorbic acid markedly inhibited ET-3-induced bronchocon-
Fig. 1 Dose-response curves of bronchoconstriction induced with (a) 
endothelin (ET-1), (b) ET-2 and (c) ET-3 with (n) or without (d) the nitric 
oxide synthase inhibitor (L-NAME; 1024 mol/L). Values for guinea-pigs 
administered endothelin only were significantly different (*p<0.05,
**P<0.01).
striction (Fig. 5). Aerosolized ET-1 (1027 mol/L) induced broncho-
constriction to the same extent as did ET-3 (1026 mol/L). However, 
isoproterenol did not significantly inhibit ET-1-induced broncho-
constriction, and the bronchodilatative effect of salbutamol was 
not affected by ascorbic acid (Fig. 6).
Fig. 2 The effects of L-arginine and nitric oxide synthase inhibitor (L-
NAME) on endothelin 3 (ET-3)-induced bronchoconstriction. Each
group represents the mean ± s. e. m. for six animals.
Fig. 3 The bronchodilatative effect of isoproterenol on endothelin-3 
(ET-3)-induced bronchoconstriction with (n) or without (d) ascorbic 
acid (1023 mol/L). Neither isoproterenol nor ascorbic acid significantly 
ffected pulmonary resistance (RL) caused by precontraction with ET-3. 
Simultaneous administration of aerosols of isoproterenol and ascorbic 
acid (o) potentiated the decrease in RL (*p<0.05, **p<0.01).
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DISCUSSION
Inhaled ET-1 and ET-3 each caused concentration-dependent 
increases in RL. In addition, pretreatment with the NO synthase 
inhibitor, L-NAME, significantly increased ET-mediated bron-
choconstriction. These findings suggest that ET-1 and ET-3
Fig. 4 The bronchodilatative effect of isoproterenol on endothelin-3 
(ET-3)-induced bronchoconstriction with (s) or without (d) ascorbic 
acid (1023 mol/L) following pretreatment with nitric oxide synthase 
inhibitor (L-NAME). Following pretreatment with L-NAME, isoproterenol 
significantly decreased pulmonary resistance (RL) caused by precontrac-
tion with ET-3. Additionally, simultaneous administration of aerosols of 
isoproterenol and ascorbic acid did not significantly potentiate the 
decrease in RL.
Fig. 5 The bronchodilatative effect of salbutamol on endothelin-3 (ET-
3)-induced bronchoconstriction with (s ) or without (d) ascorbic acid 
(1023 mol/L). Salbutamol did not effect pulmonary resistance (RL) fol-
lowing pretreatment with ET-3. Simultaneous administration of aerosols 
of salbutamol and ascorbic acid potentiated the decrease in RL 
(*p<0.05, **p<0.01)
induce the release of NO in the guinea-pig airway. However, 
high-dose ET-1 did not induce the release of NO. This agrees 
with and enhances findings from experiments using isolated 
guinea-pig airways.11 Battistini et al. reported that at concentra-
tions up to 1028 mol/L, ET-1 induced transient relaxations prior 
to the contractile response.11 Administration of the NO precur-
sor, L-arginine, given after the administration of L-NAME, 
reversed the increased RL in response to ET-3. These findings 
suggest that ET-3 administration induces the release of NO or a 
related molecule which counteracts the bronchocontractile 
response to ET-3. However, whether ET-3 can directly stimulate 
NO release from guinea-pig airway remains to be determined.
 Neither inhaled isoproterenol nor salbutamol significantly 
affected ET-3-induced bronchoconstriction, but pretreatment with 
L-NAME markedly enhanced isoproterenol-mediated relaxation. 
We therefore suggest that endogenous NO induced 
by ET-3 may attenuate isoproterenol-mediated relaxation 
responses. Ascorbic acid, an antioxidant, enhanced isoproterenol-
mediated bronchodilator response following precontraction with 
ET-3, but pretreatment with L-NAME reduced the effect of ascorbic 
acid. These findings suggest that ascorbic acid attenuates the
effect of endogenous NO onβ-adrenergic-mediated bronchodila-
for responses via its antioxidant activity. Since 1027 mol/L ET-1 
does not induce the release of NO from guinea-pig airway, ascor-
bic acid cannot possibly enhance isoproterenol-mediated bron-
chodilator responses. Endogenous NO may have beneficial 
effects by relaxing airway smooth muscle, but may also have dele-
terious effects when produced in high concentrations. It is a potent 
vasodilator and might contribute to hyperemia in asthma patients. 
NO may also increase the exudation of plasma from leaky post-
Fig. 6 The bronchodilatative effect of isoproterenol on endothelin-1 
(ET-1)-induced bronchoconstriction with (s) or without (d) ascorbic 
acid (1023 mol/L). Isoproterenol did not significantly potentiate the 
d crease in pulmonary resistance (RL).
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capillary venules in the airway. Indeed, inhibition of endogenous 
NO production significantly reduces plasma eudation and 
inflammation in the airway.12 Under normal conditions, NO can 
interact with the superoxide anion to protect lung cells. However, 
NO and the superoxide anion react rapidly to form peroxynitrite, a 
strong oxidant that may contribute to lung injury, when cytokines 
have increased production of both NO and the superoxide anion. 
The finding that nitrotyrosine, which is formed by the reaction of 
peroxynitrite with aromatic amino acids, is present in lungs of 
patients with adult respiratory distress syndrome,13 and attenuation 
by NO synthase inhibitors of experimental lung injury caused by 
oxidative stress suggest a role for NO, via peroxynitrite production, 
in mediation of lung damage.14 Peroxynitrite can directly interfere 
with the protein components of membrane receptor systems and
alter membrane properties, via lipid peroxidation, leading to indi-
rect alterations of receptor structure or diminished coupling of 
receptors to effector proteins.15 Direct oxidative modification of 
receptor systems may include redox modification of critical
thiol/disulphide groups, as has been shown forβ-ad renergic
receptors.16b Adrenergic receptors in airway smooth muscle are 
more sensitive to oxidative damage than muscarinic receptors. 
This difference has been proposed to result in oxidative stress-
induced autonomic imbalance, possibly contributing to airway 
hyper-reactivity, as in patients with asthma.17 Ascorbic acid affects 
airway hyper-reactivity.18Increases in ascorbic acid concentrations 
have been associated with increased pulmonary functions,19sug-
gesting that ascorbic acid may attenuate deterioration of lung 
function related to oxidative stress. Insufficient dietary micronutrient 
antioxidants may influence the clinical course of asthma: supple-
ment anti-oxidants, especially ascorbic acid, may be beneficial for 
some forms of airway hyper-reactivity. Recent studies suggest that 
the NO in exhaled air is formed preferentially in the airway, and 
that exhaled NO concentration is higher in asthmatic patients than 
in normal subjects.20 Endogenous NO may play a very important 
regulatory role in airway function, and may be involved in the 
pathophysiology of airway disease. While inhibition of endoge-
nous NO using arginine analogs and NO synthase inhibitor is 
likely to lead to some clinical problems, such as hypertension, it 
seems possible that certain airway diseases might be ameliorated 
by antioxidants, including those administered as aerosols. Optimal
functioning of a number of plasma membrane proteins in the res-
piratory tract, including receptors (proteins involved in signal trans-
duction) and ion channels, may require the presence of strong 
antioxidants. Antioxidant therapy thus appears to be an exciting 
new treatment for airway inflammatory disease.
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